Skip to main content

Table 2 Clinical features of patients treated with mAbs and/or antivirals

From: Lessons learned and implications of early therapies for coronavirus disease in a territorial service centre in the Calabria region: a retrospective study

Patient number

Gender, age

Comorbidities

COVID-19 vaccination

Baseline IgG anti-spike protein of SARS-CoV-2

Current or previous (within 6 months) use of immune-suppressive drugs

Initial COVID-19 therapy (time from symptom onset)

Length of hospitalisation (days)

Subsequent COVID-19 therapies, (time from symptom onset)

Clinical complications

Clinical course and outcome

1

F, 60 years

Autoimmune anaemia due to systemic lupus erythematosus

2 doses of mRNA vaccine

Negative

Rituximab

BAM/ETE (5 days)

37 days

CAS/IMD and RMD (47 days)

Respiratory failure

Severe anaemia

Non-ST-elevation myocardial infarction

Secondary depressive syndrome

Improvement of haemoglobin levels was observed after SARS-CoV-2 RNA negativisation on naso-pharyngeal swab which occurred after 12 days from CAS/IMD and RMD. The patient was subsequently discharged

2

M, 73 years

Low-grade non-infiltrating papillary urothelial bladder cancer

Type 2 diabetes mellitus hypertension hypercholesterolemia

Kidney transplant

3 doses of mRNA vaccine

Negative

Mycophenolate mofetil

tacrolimus

SOT (5 days)

40 days

None

Severe respiratory failure

diarrhoea

Complications resolved and the patient was discharged continuing low-flow oxygen therapy

3

M, 38 years

Tetraparesis due to multiple sclerosis

No

Negative

-

SOT (2 days)

8 days

RMD (6 days)

Severe respiratory failure

Complication resolved and the patient was discharged after 8 days since RMD

4

M, 56 years

Severe obesity

Type 2 diabetes mellitus Hypertension

Non-Hodgkin lymphoma

2 doses of mRNA vaccine

Negative

Rituximab

RMD (5 days)

54 days

CAS/IMD (16 days)

Severe respiratory failure

Complication resolved and the patient was discharged after 54 days since CAS/IMD continuing low-flow oxygen therapy

5

F, 41 years

Burkitt lymphoma

2 doses of mRNA vaccine

Positive

R-HYPER-C-VAD

SOT and RMD (4 days)

3 days

None

None

The patient was discharged home soon after SOT and RMD and negativisation of SARS-CoV-2 RNA on naso-pharyngeal swab occurred after 6 days from SOT and RMD

  1. F female; M male; BAM/ETE bamlanivimab/etesevimab; SOT sotrovimab; RMD remdesivir; CAS/IMD casirivimab/imdevimab; R-HYPER-C-VAD rituximab, cyclophosphamide, vincristine, adriamycin and dexamethasone; mRNA, Messenger RNA.
  2. Patients who received oxygen support by non-invasive ventilation or high-flow nasal cannula were considered to be affected by severe respiratory failure